Sacubitril/Valsartan as a New Possible Therapeutic Alternative for the Treatment of Hypertension

Desai, Anish and Anand, Sunaina and Sanghvi, Prachi and Gvalani, Aanchal and Das, Priyanka (2023) Sacubitril/Valsartan as a New Possible Therapeutic Alternative for the Treatment of Hypertension. Asian Journal of Cardiology Research, 6 (1). pp. 437-441.

[thumbnail of Sanghvi612023AJCR111301.pdf] Text
Sanghvi612023AJCR111301.pdf - Published Version

Download (253kB)


Hypertension, a major modifiable risk factor for cardiovascular disease and global mortality, affects approximately 31.1% of adults worldwide. Resistant hypertension, observed in 13-30% of hypertensive patients, poses a challenge in treatment escalation, contributing to clinical inertia. Sacubitril/valsartan, a dual-action compound comprising valsartan (an angiotensin receptor blocker) and sacubitril (a neprilysin inhibitor), has garnered approval in China and Japan for Hypertension and FDA approval for heart failure. This article aims to review the possibility of sacubitril/ valsartan as an alternative therapy for the treatment of hypertension. Clinical evidence indicates sacubitril/valsartan's efficacy in reducing blood pressure. Notably, it also demonstrates significant blood pressure reductions in patients with heart failure, emphasizing its dual benefits. The compound's superior efficacy in improving hypertension and left ventricular hypertrophy is a focus of ongoing investigations. This review highlights the role of sacubitril/valsartan as a promising therapeutic option for the management of hypertension.

Item Type: Article
Subjects: Apsci Archives > Medical Science
Depositing User: Unnamed user with email
Date Deposited: 10 Jan 2024 05:47
Last Modified: 10 Jan 2024 05:47

Actions (login required)

View Item
View Item